- Home
- JAGX vs SLRX Comparison
JAGX vs SLRX Comparison
Compare JAGX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- SLRX
- Stock Information
- Founded
- JAGX 2013
- SLRX N/A
- Country
- JAGX United States
- SLRX United States
- Employees
- JAGX N/A
- SLRX N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- SLRX Health Care
- Exchange
- JAGX Nasdaq
- SLRX Nasdaq
- Market Cap
- JAGX 3.9M
- SLRX 3.6M
- IPO Year
- JAGX N/A
- SLRX N/A
- Fundamental
- Price
- JAGX $2.12
- SLRX $4.25
- Analyst Decision
- JAGX Strong Buy
- SLRX
- Analyst Count
- JAGX 1
- SLRX 0
- Target Price
- JAGX $60.00
- SLRX N/A
- AVG Volume (30 Days)
- JAGX 227.5K
- SLRX 263.5K
- Earning Date
- JAGX 11-12-2025
- SLRX 11-13-2025
- Dividend Yield
- JAGX N/A
- SLRX N/A
- EPS Growth
- JAGX N/A
- SLRX N/A
- EPS
- JAGX N/A
- SLRX N/A
- Revenue
- JAGX $11,810,000.00
- SLRX N/A
- Revenue This Year
- JAGX $22.41
- SLRX N/A
- Revenue Next Year
- JAGX $30.00
- SLRX N/A
- P/E Ratio
- JAGX N/A
- SLRX N/A
- Revenue Growth
- JAGX 15.96
- SLRX N/A
- 52 Week Low
- JAGX $1.57
- SLRX $3.64
- 52 Week High
- JAGX $33.25
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- JAGX 50.22
- SLRX 51.81
- Support Level
- JAGX $1.93
- SLRX $3.86
- Resistance Level
- JAGX $2.40
- SLRX $4.66
- Average True Range (ATR)
- JAGX 0.20
- SLRX 0.37
- MACD
- JAGX 0.00
- SLRX -0.08
- Stochastic Oscillator
- JAGX 36.28
- SLRX 62.11
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.